

Amendments to the Claims

Please amend Claims 28, 33 and 34. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1.-25. (Cancelled)

26. (Previously Presented) A method for administering insulin to the buccal mucosa comprising spraying an effective amount of said insulin to the buccal mucosa using a metered dose inhaler, while resisting substantial inhalation of said insulin.
27. (Previously Presented) The method of Claim 26, wherein said insulin is in a mixed micelle formulation.
28. (Currently Amended) The method of Claim 27, wherein said formulation comprises:
alkali metal C₈-C₂₂ alkyl sulfate, a pharmaceutically acceptable edetate, at least one alkali metal salicylate, and at least one micelle forming compound selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanylglycine and pharmaceutically acceptable salts thereof, glycerineglycerine, polyglycerin, lysine, polylysine, polidocanol alkyl ethers and analogues thereof, triolein and mixtures thereof; wherein each of said sulfate, edetate and salicylate is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and wherein each micelle forming compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of sulfate, edetate, salicylate, and micelle forming compounds is less than 50 wt./wt. % of the formulation.
29. (Previously Presented) The method of Claim 27, wherein said micelles are 1 to 10 nm in size.

30. (Previously Presented) The method of Claim 28, wherein said alkali metal C₈-C₂₂ sulfate is sodium lauryl sulfate.
31. (Previously Presented) The method of Claim 28, wherein said edetate is an alkali metal edetate.
32. (Previously Presented) The method of Claim 28, wherein said alkali metal salicylate is sodium salicylate.
33. (Currently Amended) The method of Claim 28, wherein said micelle forming compound is lecithin, lecithin in combination with hyaluronic acid, evening of primrose oil or borage oil.
34. (Currently Amended) The method of Claim 28, wherein said formulation comprises a combination selected from the group consisting of:
 - i) sodium lauryl ~~sulfate~~ sulphate, sodium salicylate, disodium edetate, saturated phospholipid and sodium hyaluronate;
 - ii) sodium lauryl ~~sulfate~~ sulphate, sodium salicylate, disodium edetate, lecithin and sodium hyaluronate;
 - iii) sodium lauryl ~~sulfate~~ sulphate, sodium salicylate, disodium edetate, sodium hyaluronate and evening of primrose oil;
 - iv) sodium lauryl ~~sulfate~~ sulphate, sodium salicylate, disodium edetate, saturated phospholipid and bacitracin;
 - v) sodium lauryl ~~sulfate~~ sulphate, sodium salicylate, disodium edetate, saturated phospholipid, sodium hyaluronate and bacitracin; and
 - vi) sodium lauryl sulfate, sodium salicylate, disodium edetate, sodium hyaluronate, oleic acid and gamma linoleic acid.
35. (Cancelled)

36. (Previously Presented) The method of Claim 28, wherein said mixed micelle formulation further comprises water.
37. (Previously Presented) The method of Claim 26, wherein said insulin is administered in solution.